Skip to main content

PTCL

5
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
375%
Small Molecule
125%
+ 2 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Yingli Pharma
Yingli PharmaChina - Shanghai
1 program
1
YY-20394 treatmentPhase 21 trial
Active Trials
NCT04705090Unknown90Est. Jun 2023
FutureGen Biopharmaceutical
1 program
1
FG-M131Phase 1/21 trial
Active Trials
NCT07758491Not Yet Recruiting110Est. Apr 2031
MSD
MSDIreland - Ballydine
1 program
1
PembrolizumabPhase 1Monoclonal Antibody
Otsuka
OtsukaJapan - Tokushima
1 program
1
PembrolizumabPhase 1Monoclonal Antibody
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
PembrolizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03240211Active Not Recruiting37Est. May 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
VolasertibPHASE_1Small Molecule1 trial
Active Trials
NCT02757248Withdrawn0Est. Nov 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Yingli PharmaYY-20394 treatment
FutureGen BiopharmaceuticalFG-M131
Sharp TherapeuticsPembrolizumab
Boehringer IngelheimVolasertib

Clinical Trials (4)

Total enrollment: 237 patients across 4 trials

NCT04705090Yingli PharmaYY-20394 treatment

A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Start: Apr 2021Est. completion: Jun 202390 patients
Phase 2Unknown
NCT07758491FutureGen BiopharmaceuticalFG-M131

A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma

Start: Aug 2026Est. completion: Apr 2031110 patients
Phase 1/2Not Yet Recruiting
NCT03240211Sharp TherapeuticsPembrolizumab

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Start: Feb 2022Est. completion: May 202637 patients
Phase 1Active Not Recruiting
NCT02757248Boehringer IngelheimVolasertib

Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

Start: Nov 2016Est. completion: Nov 20160
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Monoclonal Antibody is the dominant modality (75% of programs)
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.